Brenntag SE — Cyborg Score 8/10

Strategic Profile

Its business model thrives on full geographic coverage, an extensive product portfolio, and a comprehensive suite of value-added services. Brenntag pursues a growth strategy based on two main pillars: organic growth and strategic acquisitions, with a diversified customer base of approximately 180,000 clients.

Cyborg Score Rationale

Market-leading position in fragmented chemical distribution with strong fundamentals (11.5% EBIT growth in 2026), diversified end-markets, and global scale. Solid governance and consistent execution offset some cyclicality in chemical markets.

Top Insights

• Global market leader with ~180,000 customers across 77+ countries and 600+ distribution sites enabling scale and pricing power
• Dual-segment strategy: Brenntag Specialties targets high-margin niche markets (pharma, nutrition, personal care); Essentials serves broad commodity chemicals
• Strong 2026 EBIT growth of 11.5% YoY demonstrates operational leverage and pricing discipline despite macro volatility
• Strategic focus on value-added services (formulation support, regulatory expertise, digital platforms) differentiate from pure commodity distributors

Named Competitors

• IMCD — Specialty chemical and ingredients distributor
• Univar Solutions — Chemical distribution and supply chain solutions
• Ashland — Industrial specialty chemicals and ingredients

Recent Developments

• (Feb 2026) Stock trading at $61.14 with market cap of $8.83B reflecting solid investor confidence
• (Jan 2026) Goldman Sachs maintained Buy rating on Brenntag stock
• (2025) Trailing twelve-month revenue of $17.3B with EBIT growth of 11.5% demonstrating strong operational performance

Open the full interactive Brenntag SE report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.